New combo therapy targets tough pancreatic cancer
NCT ID NCT07386704
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called nimotuzumab combined with radiation and chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can better control the tumor for at least a year. The trial will enroll 30 participants and track how long the cancer stays under control and overall survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Radiotherapy Oncology, Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- AI trained on thousands of pancreatic cancer cases could revolutionize diagnosis
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery